These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 16319804

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes.
    Malone JK, Yang H, Woodworth JR, Huang J, Campaigne BN, Halle JP, Yale JF, Grossman LD.
    Diabetes Metab; 2000 Dec; 26(6):481-7. PubMed ID: 11173719
    [Abstract] [Full Text] [Related]

  • 3. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Dec; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 4. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus.
    Roach P, Arora V, Campaigne BN, Mattoo V, Rangwala S, India Mix25/Mix50 Study Group.
    Diabetes Obes Metab; 2003 Sep; 5(5):311-6. PubMed ID: 12940868
    [Abstract] [Full Text] [Related]

  • 5. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 6. Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
    Roach, Koledova E, Metcalfe S, Hultman C, Milicevic Z, Romania/Russia Mix25 Study Group.
    Clin Ther; 2001 Oct; 23(10):1732-44. PubMed ID: 11726007
    [Abstract] [Full Text] [Related]

  • 7. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
    Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W.
    S Afr Med J; 2003 Mar; 93(3):219-23. PubMed ID: 12768948
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus.
    Herz M, Sun B, Milicevic Z, Erickson P, Fövènyi J, Grzywa M, Pelikanova T.
    Clin Ther; 2002 Jan; 24(1):73-86. PubMed ID: 11833837
    [Abstract] [Full Text] [Related]

  • 9. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 10. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes.
    Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS, Gack S, Gudat U.
    Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):97-103. PubMed ID: 12746761
    [Abstract] [Full Text] [Related]

  • 11. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Apr; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 12. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group.
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [Abstract] [Full Text] [Related]

  • 13. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U, Ashwell SG, Home PD.
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [Abstract] [Full Text] [Related]

  • 14. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.
    Roach P, Yue L, Arora V.
    Diabetes Care; 1999 Aug; 22(8):1258-61. PubMed ID: 10480767
    [Abstract] [Full Text] [Related]

  • 15. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan.
    Mattoo V, Milicevic Z, Malone JK, Schwarzenhofer M, Ekangaki A, Levitt LK, Liong LH, Rais N, Tounsi H, Ramadan Study Group.
    Diabetes Res Clin Pract; 2003 Feb; 59(2):137-43. PubMed ID: 12560163
    [Abstract] [Full Text] [Related]

  • 16. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

  • 17. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart.
    Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J.
    Scand J Clin Lab Invest; 2008 Sep; 68(8):739-44. PubMed ID: 19016075
    [Abstract] [Full Text] [Related]

  • 18. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [Abstract] [Full Text] [Related]

  • 19. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 20. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group.
    Roach P, Trautmann M, Arora V, Sun B, Anderson JH.
    Clin Ther; 1999 Mar 05; 21(3):523-34. PubMed ID: 10321421
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.